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Significance statement  
Acyclic nucleoside phosphonates (ANPs) play a key role in the treatment of a variety 
of infectious diseases including antiviral, antiparasitic, antimicrobial and 
antituberculotic conditions. Unfortunately, ANPs suffer of poor bioavailability due to 
the presence of an ionized phosphonic acid group. To circumvent this problem several 
prodrugs strategies have been evaluated. Among them, the ProTide approach have 
proved to be one of the most powerful technology with the phosphonoamidate 
tenofovir alafenamide fumarate (TAF, Vemlidy) approved in 2015 for the treatment 
of HIV and later in 2016 for HBV infections. Given the tremendous importance of 
phosphonoamidate prodrugs in the antiviral arena and beyond, the two synthetic 
methodologies to prepare ProTides of alkenyl ANPs, reported in this unit, are of 
extremely importance for the drug development of this class of compounds. 
 
 
Abstract  
This synthetic protocol describes two strategies for the preparation of pyrimidine 
alkenyl acyclic nucleoside phosphonoamidates (ANPs) including linear and 
trisubstituted alkenyl derivatives. For the first procedure the bis trimethylsilyl ester of 
the parent alkenyl ANPs is the key intermediate that reacts with the desired amino 
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acid ester and aryl alcohol. For the second procedure, an allyl phosphonoamidate 
bearing the ProTide promoieties is the key synthon employed as olefin partner for a 
cross metathesis reaction with an alkylated nucleobase. 
 
Keywords: ProTide, cross metathesis, acyclic nucleoside phoshonate, 
allylphosphonoamidate, prodrug, antiviral. 
 
INTRODUCTION 
 
This unit presents two different synthetic strategies for the synthesis of alkenyl acyclic 
nucleoside phosphonoamidate prodrugs. The first methodology (Basic Protocol 1) 
consists in the preparation of linear (E)-but-2-enyl pyrimidine ProTide via the bis 
trimethylsilyl ester of the parent alkenyl dimethylphosphonate nucleoside, synthetized 
following the procedure reported in Basic protocol 1 Unit 14.11 (Bessières et al., 
2001). This intermediate, obtained by treatment of the parent nucleoside with an 
excess of trimethylsilyl bromide (TMSBr) is reacted, without purification, with the 
desired amino acid ester and an excess of phenol in pyridine in the presence of 
triethylamine, aldrithiol-2 and triphenylphosphine.  
The procedure reported in Basic Protocol 2 involves in the first instance, the 
preparation of the allylphosphonoamidate intermediate obtained in the same way as in 
the Basic Protocol 1. This derivative is then reacted with alkylated nucleobase via 
olefin cross metathesis using second generation Hoveyda-Grubbs catalyst to obtain 
the branched (E)-2-methyl-but-2-enyl pyrimidine ProTide.  
 
NOTE: All glassware should be oven dried, and all reactions should be performed 
under anhydrous conditions.  
 
CAUTION: All reactions must be run in a suitable fume hood with efficient 
ventilation. Safety glasses and reagent-impermeable protective gloves should be worn 
at all time. 
Compound characterization. Chemical characterizations data are provided for all 
compounds. 1H, 31P and 13C NMR spectra were recorded in a Bruker Avance 500 
spectrometer at 500 MHz, 202 MHz and 125 MHz respectively and auto-calibrated to 
the deuterated solvent reference peak in case of 1H and 13C NMR and 85% H3PO4 for 
3 
 
31P NMR experiments. All 31P and 13C NMR spectra were proton-decoupled. 
Chemical shifts are given in parts per million (ppm) and coupling constants (J) are 
measured in Hertz (Hz) and related to multiplicities. Analytical High Performance 
Liquid Chromatography (HPLC) analysis was performed using Varian Prostar system 
(LC-Workstation-Varian Prostar 335 LC detector). High resolution mass spectrometry 
was performed on a Bruker Daltonics MicroTof-LC system (atmospheric pressure 
ionization, electron spray mass spectroscopy) in positive mode. 
 
 
BASIC PROTOCOL 1 
PREPARATION OF (E)-BUT-2-ENYL PHOSPHONOAMIDATE 
PYRIMIDINE 
The synthesis of phosphonodiamidate prodrugs of ANPs via bis trimethylsilyl ester 
has been reported by Holy et al (Jansa et al., 2011) and then successfully adapted by 
us for the synthesis of adefovir and tenofovir phosphonoamidate prodrugs (Pertusati 
et al., 2014). In this protocol we are reporting a modification of this methodology 
(Pertusati et al., 2017) for the synthesis of SP and RP isomers of (E)-N
1-(4’-O-phenyl-
(neopentyloxy-L-alanine)-phosphinyl-but-2-enyl)thymine (3a and 3b). (E)-N1-(4’-
dimethoxyphosphinyl-2’-butenyl) thymine (1), prepared according to literature 
procedures (Topalis et al., 2011), is reacted overnight with TMSBr at room 
temperature to afford intermediate 2, which after removal of the volatile is used in the 
next step without further purification. The mixture of diastereoisomers 3a and 3b is 
obtained by stirring 2 with the desired amino acid ester salt and an excess of phenol in 
presence of aldrithiol-2 and triphenylphosphine at 50 oC for 16 h. Purification by flash 
chromatography, followed by preparative HPLC, allows the separation of the two 
diastereoisomers (3a and 3b). 
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Figure 1. 
Synthesis of SP and RP isomer of (E)-N
1-(4’-O-phenyl-(neopentyloxy-L-alanine)-
phosphinyl-but-2-enyl)thymine (3a and 3b).  
 
Materials 
(E)-N1-(4’-dimethoxyphosphinyl-2’-butenyl)thymine (see Basic protocol 1 Unit 
14.11) 
Dry Argon (Ar) 
Anhydrous acetonitrile (CH3CN, Sigma-aldrich) 
Bromotrimethylsilane (TMSBr) (Sigma-aldrich) 
Anhydrous pyridine (Py, Sigma-aldrich) 
L-Alanine neopentyl ester tosylate (see Support protocol unit 15.5.8) 
Phenol (PhOH, Sigma-aldrich) 
Triethylamine (Et3N, Sigma-aldrich) 
Aldrithiol-2 (Sigma-aldrich) 
Triphenylphosphine (PPh3, Sigma-aldrich) 
Methanol (MeOH, VWR chemicals) 
Toluene (VWR chemicals) 
Hexane (VWR chemicals) 
Dichloromethane (CH2Cl2, VWR chemicals) 
Acetonitrile HPLC grade (CH3CN, VWR chemicals) 
Water HPLC grade (VWR chemicals) 
Anhydrous MgSO4 (Sigma-aldrich) 
Silica gel (35-70µ, 60A; Fisher) 
Sand (Sigma-Aldrich) 
Deuterated methanol (CD3OD), 99.8% pure (Goss Scientific, CD3OD is used for 
NMR characterization). 
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Deuterated chloroform (CDCl3), 99.8% pure, (Goss Scientific, CDCl3 is used for 
NMR characterization). 
 
Magnetic stirring and heating plate 
Oil bath 
Condenser/airflux condenser 
100-mL round-bottom flask 
100 mL separatory funnel 
Glass funnel 
Analytical TLC plate (aluminum-backed TLC plates, precoated with silica gel 60 F254, 
0.2 mm; Merck Kieselgel) 
Preparative TLC plate (aluminum-backed TLC plates, precoated with silica gel 60 
F254, 20 x 20, 500-2000 µm; Merck Kieselgel) 
Preparative TLC chamber 
Rotary evaporator equipped with vacuum pump 
Vacuum desiccator 
Glass flash chromatography column 
Preparative HPLC (Varian Prostar; LC Workstation-Varian Prostar 335 LC detector; 
Varian Pursuit XRs 5 C18 150 x 21.2 mm reverse phase column) 
UV light source 
 
Prepare phosponoamidate 3 
1. Place 0.087 g (0.275 mmol) of (E)-N1-(4’-dimethoxyphosphinyl-2’-
butenyl)thymine (1) in a 100 mL round bottom flask containing a magnetic stir 
bar and apply an argon atmosphere. 
2. Add 10 mL of anhydrous acetonitrile. 
3. While stirring, add 0.182 mL (1.38 mmol) of TMSBr at room temperature and 
continue stirring for 16 h under an argon atmosphere to obtain a brown 
solution. 
4. After this period, evaporate the solvent under reduced pressure on a rotary 
evaporator without any contact with air to afford 2 as a brown foamy solid 
crude mixture. 
5. Dry the crude residue under vacuum for 1 h (oil pump). 
6. Dissolve the solid in 5 mL of anhydrous pyridine under an argon atmosphere. 
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7. Add 0.091 g (0.275 mmol) of dry L-alanine neopentyl ester tosylate, 0.432 g 
(1.65 mmol) of phenol and 3.4 mL (24.9 mmol) of triethylamine. 
8. Place the reaction mixture in an oil bath, heat at 50 ˚C and stir for 10 min to 
obtain a yellow solution. 
9. In a separate flask, prepare a solution with 0.155 g (1.65 mmol) of aldrithiol-2 
and 0.363 g (1.65 mmol) of triphenylphosphine in 5 mL of anhydrous pyridine 
under an argon atmosphere. 
10. Add the aldrithiol/triphenylphosphine solution to the stirring reaction mixture 
and keep at 50 ˚C for 4 h. 
11. Allow cooling down to room temperature. 
12. Evaporate the reaction mixture to dryness using a rotary evaporator under 
reduced pressure. 
13. Add a mixture of methanol, water, toluene and hexane 1:1:1:1 (10/10/10/10 
mL) to the residue and transfer the mixture into a 100 mL separatory funnel. 
14. Remove the upper layer (hexane/toluene) and wash the lower phase with a 
mixture of toluene and hexane 1:1 (v/v) three times (3 x 10 mL). 
15. Remove the upper layer and extract the lower layer (MeOH/H2O) three times 
with CH2Cl2 (3 x 20 mL). 
16. Combine the CH2Cl2 phases, dry over MgSO4, filter by gravity filtration and 
then evaporate using a rotary evaporator under reduced pressure.  
17. Dissolve the crude product in the minimum amount of CH2Cl2 and carefully 
place the solution on top of a glass flash chromatography column packed with 
silica gel in CH2Cl2. Elute a gradient solution of CH2Cl2/MeOH (99:1 to 93:7 
v/v). 
18. Monitor the fractions by TLC and visualize by UV light, combine the fractions 
containing the products and evaporate to dryness using a rotary evaporator 
under reduced pressure. 
19. Complete the purification of the products by preparative thin layer 
chromatography on silica gel. 
Dissolve the crude product in the minimum amount of CH2Cl2 and apply the 
sample on a TLC plate about 1.5 cm from the bottom edge and allow the 
solvent to evaporate. Place the TLC plate in a separation chamber containing 
200 mL 95:5 (v/v) CH2Cl2/MeOH solution. When the solvent reaches 1.5 cm 
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from the upper edge remove the TLC plate and allow the solvents to 
evaporate. 
20. Scrape off the backing material of the desired band, visualized using UV light, 
and extract it with minimal 90:10 (v/v) CH2Cl2/MeOH solution. Filter the 
silica off using a glass filter funnel, wash it using a small amount of 90:10 
(v/v) CH2Cl2/MeOH solution and concentrate the filtrate using a rotary 
evaporator under reduced pressure.  
21. Dissolve the isomers mixture in MeOH (HPLC grade) and separate them by 
preparative HPLC (20 ml/min, gradient eluting system CH3CN/H2O – from 
10/90 to 100/0, 30 min) to afford compounds as foamy solids. 
22. Characterise the compound by 31P NMR, 1H NMR, 13C NMR and MS. 
 
31P NMR spectra documented below were obtained with proton decoupling 
 
(E)-N1-(4’-O-phenyl-(neopentyloxy-L-alanine)-phosphinyl-but-2-enyl)thymine (3a 
and 3b).  
3a: Yield 0.021 g (16%). Rf = 0.32 (CH2Cl2/MeOH - 95:5). 
31P-NMR (202 MHz, CD3OD) δP 29.23. 
1H-NMR (500 MHz, CD3OD) δH 7.41 (1H, d, J = 1.1 Hz, H-6), 7.38-7.34 (2H, m, CH-
Ph), 7.21-7.18 (3H, m, CH-Ph), 5.83-5.79 (2H, m, NCH2CH= and =CHCH2P), 4.36 
(2H, t, J =4.8 Hz, CH2N), 4.05-3.99 (1H, m, CHCH3), 3.87, 3.77 (2H, AB, JAB = 10.5 
Hz, CH2C(CH3)3), 2.87 (2H, ddd, J = 6.4 and 4.6 Hz, 
2JPH=20.5 Hz, CH2P), 1.87 (3H, 
d, J =1.2 Hz, CH3), 1.26 (3H, d, J =7.3 Hz, CHCH3), 0.96 (9H, s, C(CH3)3)
. 
31C-NMR (125 MHz, CDCl3) δC 174.05 (d, 3JPC = 4.9 Hz, COO), 163.9 (C-4), 150.67 
(C-2), 150.38 (d 2JCP = 9.1 Hz, C-ipso Ph), 139.74 (CH-6), 129.77 (CH-Ph), 129.47 
(d, 2JPC = 10.7 Hz, =CHCH2P), 129.21 (d, 
3JPC = 14.7 Hz, NCH2CH=), 124.64 (CH-
Ph), 120.68 (d, 3JPC = 4.5 Hz, CH-Ph), 111.00 (C-5), 74.71 (CH2C(CH3)3), 49.73 
(CHCH3 ), 49.49 (CH2N), 32.44 (d, 
1JPC = 127.2 Hz, CH2P), 29.69 (C(CH3)3), 26.32 
(C(CH3)3), 21.53 (d 
3JPC = 6.3 Hz, CHCH3), 10.87 (CH3).  
HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 
100/0 in 30 min, 1ml/min, λ = 254 nm and 263 nm, showed one peak with tR 16.06 
min. 
MS(ESI+) m/z= 500.2 [M + Na+] (100%). 
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3b: Yield 0.013 g (10%). Rf = 0.29 (CH2Cl2/MeOH - 95:5). 
31P-NMR (202 MHz, CDCl3) δP 28.51. 
1H-NMR (500 MHz, CD3OD) δH 7.37 (1H, d, J=1.1 Hz, H-6), 7.35-7.32 (2H, m, CH-
Ph), 7.22-7.17 (3H, m, CH-Ph), 5.79-5.76 (2H, m, NCH2CH= and =CHCH2P), 4.35 
(2H, m, CH2N), 3.91, 3.82 (2H, AB, JAB = 10.5 Hz, CH2C(CH3)3), 3.67-3.60 (1H, m, 
CHCH3), 2.86-2.80 (2H, m, CH2P), 1.87 (3H, s, CH3), 1.38 (3H, d, J = 7.2 Hz, 
CHCH3), 0.99 (9H, s, C(CH3)3). 
31C-NMR (125 MHz, CDCl3) δC 173.79 (d, 3JPC =4.9 Hz, COO), 164.01 (C-4), 150.72 
(C-2), 150.43 (d, 2JCP = 7.84 Hz, C-ipso Ph), 139.66 (CH-6), 129.77 (CH-Ph), 129.24 
(d, 2JP C= 14.7 Hz, =CHCH2P), 125.16 (d, 
2JPC = 11.0 Hz, NCH2CH=), 124.86 (CH-
Ph), 120.47 (d, 3JPC = 4.9 Hz, CH-Ph), 111.05 (C-5), 74.78 (CH2C(CH3)), 49.62 
(CHCH3), 49.23 (CH2N), 32.79 (d, 
1JPC = 130.8 Hz, CH2P), 29.70 (C(CH3)3), 29.36 
(C(CH3)3), 21.79 (d, 
3JPC = 2.5 Hz, CHCH3), 12.30 (CH3). 
HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 
100/0 in 30 min, 1ml/min, λ = 254 nm and 263 nm, showed one peak with tR 16.14 
min. 
MS(ESI+) m/z= 500.2 [M + Na+] (100%). 
 
 
BASIC PROTOCOL 2 
PREPARATION OF (E)-2-METHYL-BUT-2-ENYL PHOSPHONOAMIDATE 
PYRIMIDINE 
This protocol describes the preparation of phosphonoamidate prodrugs of 
trisubstituted alkenyl acyclonucleoside using cross-metathesis reaction. Olefin cross-
metathesis methodology has been used for the direct synthesis of a vast array of 
unsaturated ANPs analogues including bis-POM, bis-POC, and alkoxyesters prodrugs 
(Hamada et al., 2013; Pradère et al., 2011). Only very recent application of such 
procedure for the preparation of ProTides has been reported (Bessières et al., 2018). 
Despite some similarities, the synthetic strategy we are reporting here differs from 
that published by Agrofoglio et al. 
This methodology involves first the synthesis of the aryloxy allylphosphonoamidate 6 
as the key synthon. Briefly, the commercial dimethyl allylphosphonate 4 is converted 
into the corresponding silyl ester 5 in presence of an excess of TMSBr and 2,6-
lutidine as acid scavenger. After removal of the volatile 5 is used without further 
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purification and treated with the amino acid ester hydrochloride and an excess of aryl 
alcohol in presence of aldrithiol-2 and triphenylphosphine at 50oC for 16 h to obtain 
the desired allylphosphonoamidate 6. 
The second olefin partner for the cross metathesis reaction (9 and 10) was synthesized 
by N1-substitution using 3-bromo-2-methylpropene (Bessieres et al., 2016). 
As illustrated in Figure 2, the allylphosphonoamidate intermediate 6 is then sonicated 
with 2-methylallyl pyrimidines 9 and 10 in presence of Hoveyda-Grubbs second 
generation catalyst in CH2Cl2 at reflux for 24 h, to obtain the final ProTides 11 and 
12. 
 
 
 
Figure 2. Preparation of (E)-N1-(4’-O-(1-Naphthyl)-(isopropyloxy-L-Alanine)-
phosphinyl-2’-methyl-but-2’-enyl) pyrimidines (11 and 12) via cross metathesis using 
O-(1-naphthyl)-(isopropyloxy-L-Alanine)-allylphosphonate (6) as key synthon. 
 
Materials 
Dimethyl allylphosphonate (4) (Alfa Aesar) 
2,6-Lutidine (Sigma-aldrich) 
Dry Argon (Ar) 
Anhydrous acetonitrile (CH3CN, Sigma-aldrich) 
Bromotrimethylsilane (TMSBr) (Sigma-aldrich) 
Anhydrous pyridine (Py, Sigma-aldrich) 
L-Alanine isopropyl ester hydrochloride (Sigma-aldrich) 
1-Naphthol (1-NaphOH, Sigma-aldrich) 
Triethylamine (Et3N, Sigma-aldrich) 
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Aldrithiol-2 (Sigma-aldrich) 
Triphenylphosphine (PPh3, Sigma-aldrich) 
Ethyl acetate (EtOAc, VWR chemicals) 
Hexane (VWR chemicals) 
Methanol (MeOH, VWR chemicals) 
Uracil (7) (Sigma-aldrich) 
Thymine (8) (Sigma-aldrich) 
N,O-Bis(trimethylsilyl)acetamide (BSA, Sigma-aldrich) 
3-Bromo-2-methylpropene (Sigma-aldrich) 
Sodium iodide (NaI, Sigma-aldrich) 
Chlorotrimethylsilane (TMSCl, Sigma-aldrich) 
Anhydrous dichloromethane (CH2Cl2, Sigma-aldrich) 
Hoveyda-Grubbs Catalys 2nd Generation (Sigma-aldrich) 
Dichloromethane (CH2Cl2, VWR chemicals) 
2-propanol (VWR chemicals) 
Acetonitrile HPLC grade (CH3CN, VWR chemicals) 
Water HPLC grade (VWR chemicals) 
Anhydrous MgSO4 (Sigma-aldrich) 
Magnetic stirring and heating plate 
Oil bath 
Condenser/airflux condenser 
50-, 100-mL round-bottom flask 
Analytical TLC plate (aluminum-backed TLC plates, precoated with silica gel 60 F254, 
0.2mm; Merck Kieselgel) 
250 mL separating funnel 
Glass funnel 
Filter paper 
Rotary evaporator equipped with vacuum pump 
Vacuum desiccator 
Fisherbrand 11203 Ultrasonic Cleaner 
Automatic Flash Chromatography (Biotage Isolera One) 
Preparative HPLC (Varian Prostar; LC Workstation-Varian Prostar 335 LC detector; 
Varian Pursuit XRs 5 C18 150 x 21.2 mm reverse phase column) 
UV light source 
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Deuterated methanol (CD3OD), 99.8% pure (Goss Scientific, CD3OD is used for 
NMR characterization). 
 
 
Preparation of allylphosphonoamidate derivative 
1. Place 0.500 g (3.3 mmol) of 4 in a 100 mL round bottom flask containing a 
magnetic stir bar and apply an argon atmosphere. 
2. Add 25 mL anhydrous acetonitrile and 1.55 mL (13.3 mmol) of 2,6-lutidine. 
3. While stirring add 2.20 mL (16.6 mmol) of TMSBr at room temperature and 
continue stirring for 16 h under an argon atmosphere to obtain a brown 
solution. 
4. After this period, evaporate the solvent under reduced pressure on a rotary 
evaporator without any contact with air to afford 5 as a brown foamy solid 
crude mixture. 
5. Dry the crude residue under vacuum for 1 h (oil pump). 
6. Dissolve the solid in 10 mL of anhydrous pyridine under an argon atmosphere. 
7. Add 0.558 g (3.3 mmol) of dry L-alanine isopropyl ester hydrochloride, 2.88 g 
(19.9 mmol) of dry 1-naphthol and 6.9 mL (49.9 mmol) of triethylamine. 
8. Place the reaction mixture in an oil bath, heat at 50 ˚C and stir for 10 min to 
obtain a yellow solution. 
9. Prepare a solution with 4.40 g (19.9 mmol) of aldrithiol-2 and 5.24 g (19.9 
mmol) of triphenylphosphine in 10 mL of anhydrous pyridine under an argon 
atmosphere. 
10. Add the aforementioned solution to the stirring reaction mixture while stirring 
and keep at 50 ˚C for 16 h. 
11. Allow cooling down to room temperature. 
12. Monitor the reaction by TLC using 4:6 (v/v) EtOAc /hexane and visualize by 
UV light (6 Rf = 0.58). 
13. Evaporate the reaction mixture to dryness using a rotary evaporator under 
reduced pressure. 
14. Purify the residue by Biotage Isolera One 
Dissolve the crude product in the minimum amount of CH2Cl2/ solution and 
carefully place into a 100 g SNAP cartridge ULTRA. Purify using 100 ml/min 
gradient eluent system EtOAc/hexane 10% 1CV, 10-100% 12CV, 100% 2CV. 
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15. Monitor the fractions by TLC and visualize by UV light, combine the fractions 
containing the pure product and evaporate to dryness using a rotary evaporator 
under reduced pressure to afford compound 6 as yellow oil. 
16. Characterise the compounds by 31P NMR, 1H NMR and 13C NMR. 
 
31P NMR spectra documented below were obtained with proton decoupling. 
 
O-(1-naphthyl)-(isopropyloxy-L-Alanine)-allylphosphonate (6). Yield 0.940 g (79%). 
Rf : 0.58 (EtOAc/Hexane - 4:6).  
31P NMR (202 MHz, CD3OD) δP: 30.01, 29.43. 
1H NMR (500 MHz, CD3OD) δH: 8.19 (d, J = 7.2 Hz, 1H, ArH), 7.89 (d, J = 7.9 Hz 
1H, ArH), 7.71-7.69 (m, 1H, ArH), 7.58-7.40 (m, 4H, ArH), 6.07-5.91 (m, 1H, CH=), 
5.38-5.28 (m, 2H, CH2=), 5.95-4.82 (m, 1H, CH(CH3)2), 3.99-3.97 (m, 1H, CHCH3 L-
Ala), 3.03-2.93 (m, 2H, CH2P), 1.25 (d, J = 7.8 Hz, 1.5H, CHCH3 L-Ala), 1.21-1.10 
(m, 7.5H, CHCH3 L-Ala, CH(CH3)2). 
13C NMR (125 MHz, CD3OD) δC: 173.5 (d, 3JC-P = 4.2 Hz, C=O, ester), 173.1 (d, 
3JC-P = 4.2 Hz, C=O, ester), 146.4 (d, 
2JC-P = 8.5 Hz, C-O, Ph), 146.3 (d, 
2JC-P = 8.5 
Hz, C-O, Ph), 134.9 (C-Ar), 127.4 (2JC-P = 9.3 Hz, CH=), 123.3 (
2JC-P = 10.9 Hz, 
CH=), 126.9 (d, 3JC-P = 5.6 Hz C-Ar), 126.8 (d, 
3JC-P = 4.9 Hz C-Ar), 126.3 (CH-Ar), 
125.95 (CH-Ar), 125.90 (CH-Ar), 125.1 (CH-Ar), 125.0 (CH-Ar), 124.3 (CH-Ar), 
124.2 (CH-Ar), 121.6 (CH-Ar), 121.4 (CH-Ar), 119.7 (d, 3JC-P = 14.2 Hz CH2=), 
119.6 (d, 3JC-P = 13.8 Hz CH2=), 115.4 (d, 
3JC-P = 4.1 Hz CH-Ar), 115.2 (d, 
3JC-P = 3.4 
Hz CH-Ar), 68.6 (CH(CH3)2), 68.5 (CH(CH3)2), 49.6 (CHCH3 L-Ala), 49.4 (CHCH3 
L-Ala), 33.7 (d, 1JC-P = 129.0 Hz CH2P), 33.5 (d, 
1JC-P = 129.6 Hz CH2P), 20.5 
(CH(CH3)2), 20.4 (CH(CH3)2), 20.3 (CH(CH3)2), 19.7 (d, 
3JC-P = 5.4 Hz, CHCH3 L-
Ala), 19.1 (d, 3JC-P = 5.4 Hz, CHCH3 L-Ala). 
 
Prepare N1-2’-methylallyl-pyrimidines 
17. Dissolve 1.5 g of nucleobase (13.3 mmol of 7, 11.8 mmol of 8) in 25 mL of 
anhydrous acetonitrile in a 100 mL round bottom flask containing a magnetic 
stir bar and apply an argon atmosphere. 
18. While stirring add N,O-Bis(trimethylsilyl)acetamide  (BSA) 
For 9: 8.18 mL (33.4 mmol) of BSA 
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For 10: 7.20 mL (29.7 mmol) of BSA 
19. Place the reaction mixture in an oil bath, heat at reflux temperature and stir 
until a clear solution is observed (usually 10 min). 
20. Add under an argon atmosphere 3-bromo-2-methylpropene, NaI and 
chlorotrimethylsilane 
For 9: 2.40 mL (23.7 mmol) of 3-bromo-2-methylpropene, 1.96 g (13.1 mmol) 
of NaI, 1.51 mL (11.8 mmol) of chlorotrimethylsilane 
For 10: 2.70 mL (26.7 mmol) of 3-bromo-2-methylpropene, 2.21 g (14.7 
mmol) of NaI, 1.70 mL (13.3 mmol) of chlorotrimethylsilane 
21. Stir under reflux and under an argon atmosphere for 16 h. 
22. Monitor the reaction by TLC and visualize with UV light using 7:3 (v/v) 
EtOAc/hexane and visualize by UV light (9 Rf : 0.25; 10 Rf : 0.45). 
23. Evaporate the solvent to dryness under reduced pressure on a rotary 
evaporator. 
24. Dissolve the residue in 50 mL of EtOAc and wash the mixture in sequence 
with 20 mL of NaHCO3 aqueous saturated solution, 20 mL of Na2SO4 aqueous 
saturated solution and 20 mL of H2O using a 250 mL separating funnel. 
25. Dry the organic phase over anhydrous MgSO4, filter by gravity filtration and 
evaporate the solution to dryness using a rotary evaporator under reduced 
pressure. 
26. Purify the residue by Biotage Isolera One  
Dissolve the crude product in the minimum amount of CH2Cl2 and carefully 
place into a 50 g SNAP cartridge ULTRA. Purify using a 100 ml/min gradient 
eluent system EtOAc/hexane 17% 1CV, 17-100% 10CV, 100% 3CV. 
27. Monitor the fractions by TLC and visualize by UV light, combine the fractions 
containing the pure product and evaporate to dryness using a rotary evaporator 
under reduced pressure to afford compounds 9 and 10 as pale-yellow solids. 
28. Characterise the compounds by 1H NMR. 
 
N1-2’-methylallyl-uracil (9). Yield 1.2 g (51%). Rf : 0.25 (EtOAc/Hexane - 7:3). 
1H NMR (500 MHz, CD3OD) δH: 7.50 (d, J = 7.8 Hz, 1H, H-6), 5.71 (d, J = 7.8 Hz, 
1H, H-5), 4.98 (s, 1H, CH2=), 4.81 (s, 1H, CH2=), 4.33 (s, 2H, CH2-N), 1.76 (s, 3H, 
CH3, alkene). 
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N1-2’-methylallyl-thymine (10). Yield 2.1 g (98%). Rf : 0.45 (EtOAc/Hexane - 7:3). 
1H NMR (500 MHz, CD3OD) δH: 7.34 (s, 1H, H-6), 4.98 (s, 1H, CH2=), 4.80 (s, 1H, 
CH2=), 4.30 (s, 2H, CH2-N), 1.89 (s, 3H, CH3, base), 1.76 (s, 3H, CH3, alkene). 
 
 
Olefin cross metathesis  
23. Dissolve 0.150 g of the allylphosphonoamidate 6 (415.0 µmol) in 10 mL of 
anhydrous dichloromethane in a 50 mL round bottom flask containing a 
magnetic stir bar and apply an argon atmosphere. 
24. Add N1-2’-methylallyl-pyrimidine 
For 11: 0.137 g (830.1 µmol) of 9. 
For 12: 0.150 g (830.1 µmol) of 10. 
25. Add 0.039 g (62.2 µmol, 15 mol%) of Hoveyda-Grubbs second generation 
catalyst. 
Note: The total amount of second generation Hoveyda-Grubbs catalyst is introduced in three 
equal portions of 5 mol% at t = 0, 2, 4 h over the course of the reaction. 
26. Sonicate the reaction mixture at 37 MHz for 24 h. 
27. Monitor the reaction by TLC using 95:5 (v/v) CH2Cl2/MeOH and visualize by 
UV light (11 Rf: 0.22; 12 Rf: 0.24). 
28. Evaporate the reaction mixture to dryness using a rotary evaporator. 
Dissolve the crude product in the minimum amount of 99:1 (v/v) 
CH2Cl2/MeOH solution and carefully place into a 50 g SNAP cartridge 
ULTRA. Purify using a 100 ml/min gradient eluent system MeOH/CH2Cl2 1% 
1CV, 1-10% 12CV, 10% 2CV. 
29. Monitor the fractions by TLC and visualize by UV light, combine the fractions 
containing a mixture of E and Z isomers of the compound and evaporate to 
dryness using a rotary evaporator under reduced pressure. 
30. Separate the two isomers by reverse phase chromatography. 
For 11: Dissolve the product in MeOH (HPLC gradient) and purify by 
preparative HPLC (20 ml/min, isocratic eluting system CH3CN/H2O - 35/65, 
30 min.) to afford the compound as pale yellow foamy solid. 
For 12: Dissolve the product in MeOH and carefully place into a 60 g SNAP 
cartridge KP-C18-HS, and purify by reverse phase flash chromatography 
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using 100 ml/min, isocratic eluent system CH3CN/H2O 40/60 12CV, to afford 
the compound as pale yellow foamy solid. 
 
31. Characterise the compounds by 31P NMR, 1H NMR and 13C NMR, HRMS and 
HPLC. 
 
31P NMR spectra documented below were obtained with proton decoupling. 
 
(E)-N1-(4’-O-(1-naphthyl)-(isopropyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-
enyl)uracil (11). Yield 0.028 g (14%). Rf = 0.22 (CH2Cl2/MeOH - 95:5). 
31P NMR (202 MHz, CD3OD) δP: 30.28, 29.49. 
1H NMR (500 MHz, CD3OD) δH: 8.14-8.13 (m, 1H, ArH), 7.88-7.84 (m, 1H, ArH), 
7.70-7.67 (m, 1H, ArH), 7.58-7.49 (m, 3H, ArH), 7.44-7.38 (m, 2H, H-6, ArH), 5.61-
5.57 (m, 1.5H, CH=, H-5), 5.51-5.47 (m, 0.5H, CH=), 4.93 (sept, J = 6.5 Hz, 0.5H, 
CH(CH3)2), 4.88-4.84 (m, 0.5H, CH(CH3)2), 4.33-4.25 (m, 2H, CH2-N), 4.04-3.97 (m, 
1H, CHCH3 L-Ala), 3.08-2.90 (m, 2H, CH2P), 1.65 (bs, 3H, CH3, alkene), 1.27 (d, J = 
7.0 Hz, 1.5H, CHCH3 L-Ala), 1.20 (d, J = 6.2 Hz, 1.5H, CH(CH3)2), 1.19 (d, J = 6.2 
Hz, 1.5H, CH(CH3)2), 1.17 (d, J = 6.9 Hz, 1.5H, CHCH3 L-Ala), 1.12 (d, J = 6.2 Hz, 
1.5H, CH(CH3)2), 1.15 (d, J = 6.2 Hz, 1.5H, CH(CH3)2). 
13C NMR (125 MHz, CD3OD) δC: 173.6 (d, 3JC-P = 4.3 Hz, C=O, ester), 173.2 (d, 
3JC-P = 4.1 Hz, C=O, ester), 165.17 (C-4), 165.15 (C-4), 151.5 (C-2), 151.4 (C-2), 
146.5 (d, 2JC-P = 9.7 Hz, C-O, Ph), 146.3 (d, 
2JC-P = 9.7 Hz, C-O, Ph), 145.2 (C-6), 
145.1 (C-6), 135.2 (d, 3JC-P = 14.5 Hz, C=), 135.4 (d, 
3JC-P = 14.5 Hz, C=), 134.9 (C-
Ar), 127.5 (CH-Ar), 127.4 (CH-Ar), 126.8 (d, 3JC-P = 4.9 Hz C-Ar), 126.6 (d, 
3JC-P = 
5.1 Hz C-Ar), 126.3 (CH-Ar), 126.1 (CH-Ar), 125.2 (CH-Ar), 125.1 (CH-Ar), 124.3 
(CH-Ar), 124.2 (CH-Ar), 121.5 (CH-Ar), 121.3 (CH-Ar), 117.4 (2JC-P = 11.0 Hz, 
CH=), 116.9 (2JC-P = 11.0 Hz, CH=), 115.4 (d, 
3JC-P = 3.8 Hz CH-Ar), 115.1 (d, 
3JC-P 
= 3.8 Hz CH-Ar), 101.2 (C-5), 68.69 (CH(CH3)2), 68.66 (CH(CH3)2), 53.7 (d, 
4JC-P = 
2.3 Hz, CH2-N), 53.5 (d, 
4JC-P = 2.3 Hz, CH2-N), 49.7 (CHCH3 L-Ala), 49.5 (CHCH3 
L-Ala), 28.3 (d, 1JC-P = 128.9 Hz CH2P), 28.1 (d, 
1JC-P = 129.8 Hz CH2P), 20.6 
(CH(CH3)2), 20.56 (CH(CH3)2), 20.52 (CH(CH3)2), 20.4 (CH(CH3)2), 19.8 (d, 
3JC-P = 
5.8 Hz, CHCH3 L-Ala), 19.1 (d, 
3JC-P = 5.5 Hz, CHCH3 L-Ala), 13.3 (d, 
4JC-P = 2.4 
Hz, CH3, alkene), 13.2 (d, 
4JC-P = 2.2 Hz, CH3, alkene). 
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HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 
100/0 in 30 minutes, 1ml/min, λ = 254 nm and 263 nm, showed one peak with tR 15.57 
min.  
HRMS (ESI): m/z [M+Na]+ calcd for C25H30N3O6P: 522.1770, found: 522.1764. 
 
(E)-N1-(4’-O-(1-naphthyl)-(isopropyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-
enyl)thymine (12). Yield 0.075 g (36%). Rf = 0.24 (CH2Cl2/MeOH - 95:5). 
31P NMR (202 MHz, CD3OD) δP: 30.32, 29.54. 
1H NMR (500 MHz, CD3OD) δH: 8.13-8.12 (m, 1H, ArH), 7.89-7.87 (m, 1H, ArH), 
7.71-7.68 (m, 1H, ArH), 7.57-7.48 (m, 3H, ArH), 7.45-7.39 (m, 1H, ArH), 7.27 (s, 
0.5H, H-6), 7.26 (s, 0.5H, H-6), 5.61-5.56 (m, 1H, CH=), 4.93-4.84 (m, 1H, 
CH(CH3)2), 4.32-4.26 (m, 2H, CH2-N), 4.01-3.91 (m, 1H, CHCH3 L-Ala), 3.08-2.86 
(m, 2H, CH2P), 1.75 (s, 3H, CH3, base), 1.67 (s, 3H, CH3, alkene), 1.27 (d, J = 6.9 
Hz, 1.5H, CHCH3 L-Ala), 1.20-1.16 (m, 4.5H, CHCH3 L-Ala, CH(CH3)2), 1.13-1.10 
(m, 3H, CH(CH3)2). 
13C NMR (125 MHz, CD3OD) δC: 173.5 (d, 3JC-P = 3.9 Hz, C=O, ester), 173.1 (d, 
3JC-P = 3.5 Hz, C=O, ester), 165.34 (C-4), 165.32 (C-4), 151.69 (C-2), 151.61 (C-2), 
146.5 (d, 2JC-P = 9.5 Hz, C-O, Ph), 146.3 (d, 
2JC-P = 9.5 Hz, C-O, Ph), 140.94 (C-6), 
140.92 (C-6), 135.5 (d, 3JC-P = 14.3 Hz, C=), 135.1 (d, 
3JC-P = 14.7 Hz, C=), 134.9 
(C-Ar), 127.48 (CH-Ar), 127.46 (CH-Ar), 126.7 (d, 3JC-P = 5.1 Hz C-Ar), 126.6 (d, 
3JC-P = 5.1 Hz C-Ar), 126.3 (CH-Ar), 126.0 (CH-Ar), 125.16 (CH-Ar), 125.11 (CH-
Ar), 124.3 (CH-Ar), 124.2 (CH-Ar), 121.4 (CH-Ar), 121.3 (CH-Ar), 117.1 (2JC-P = 
11.1 Hz, CH=), 116.6 (2JC-P = 10.7 Hz, CH=), 115.3 (d, 
3JC-P = 3.5 Hz CH-Ar), 115.1 
(d, 3JC-P = 3.9 Hz CH-Ar), 110.1 (C-5), 68.69 (CH(CH3)2), 68.65 (CH(CH3)2), 53.5 (d, 
4JC-P = 2.7 Hz, CH2-N), 53.2 (d, 
4JC-P = 2.3 Hz, CH2-N), 49.7 (CHCH3 L-Ala), 49.5 
(CHCH3 L-Ala), 28.3 (d, 
1JC-P = 129.0 Hz CH2P), 28.1 (d, 
1JC-P = 130.0 Hz CH2P), 
20.55 (CH(CH3)2), 20.54 (CH(CH3)2), 20.48 (CH(CH3)2), 20.40 (CH(CH3)2), 19.8 (d, 
3JC-P = 5.5 Hz, CHCH3 L-Ala), 19.1 (d, 
3JC-P = 5.9 Hz, CHCH3 L-Ala), 13.3 (d, 
4JC-P 
= 2.3 Hz, CH3, alkene), 13.2 (d, 
4JC-P = 2.7 Hz, CH3, alkene), 10.8 (CH3, base). 
HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 
100/0 in 30 minutes, 1ml/min, λ = 254 nm and 263 nm, showed one peak with tR 16.26 
min. 
HRMS (ESI): m/z [M+Na]+ calcd for C26H32N3O6P: 536.1926, found: 536.1921. 
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COMMENTARY 
Background Information 
In the last years, the ProTide approach, pioneered by Chris Mcguigan’s group, has 
displayed a great deal of success in the development of nucleoside-based antivirals 
and anticancer drugs. Sofosbuvir (Nakamura et al., 2016) and TAF (Abdul Basit et al., 
2017; Ray et al., 2016) on the market for viral infections, and Acelerin (Slusarczyk et 
al., 2014) and NUC 3373 (McGuigan et al., 2011) in clinical trials (Phase III and 
Phase I) for patients with advanced solid tumours, are the undeniable proofs of how 
powerful is this technology.  
While there are several efficient procedures to synthesize phosphoroamidate 
nucleosides, the phosphonoamidate cognate class especially of acyclic nucleoside 
phosphonates (ANPs) lacks of such plethora of synthetic methodologies (Pradere et 
al., 2014). 
We were able to synthetize prodrugs of adefovir and tenofovir in moderate yield 
(Pertusati et al., 2014) by adaption of the one-pot procedure for preparing 
phosphonodiamidate, reported by Jansa et al 2011 (Jansa et al., 2011). Unfortunately, 
when these conditions were applied on the alkenyl-pyrimidine substrate, only traces 
of the desired phosphonoamidate product were detected with the phosphonodiamidate 
being the major product. Increasing the equivalents of the aryl-alcohol (6 equivalents) 
with respect to the amino acid (1 equivalent) proved necessary to obtain the desired 
phosphonoamidate in moderate yield as reported in Basic Protocol 1 for the 
preparation of linear (E)-4-phosphonoamidate-but-2’en-1’-yl pyrimidine (Pertusati et 
al., 2017). However, we discovered that this methodology suffers from the limitation 
that only linear olefin must be employed, as with trisubstituted alkenyl derivatives no 
formation of the desired ProTide was observed in our hand. This finding prompted us 
to investigate and then develop the methodology reported in Basic Protocol 2 using a 
cross-metathesis reaction for the direct synthesis of branched unsaturated ANP 
phosphonoamidates. At the time we started this investigation, no application of such 
procedure for the synthesis of ProTides was yet reported. However, recently, a paper 
reporting on the use of the cross metathesis for the synthesis of ProTide derivatives of 
linear (E)-but-2-enyl nucleoside scaffold, was published by Agrofoglio et al. 
(Bessières et al., 2018)  
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Both our and Agrofofoglio’s procedures involves the preparation of the aryl 
allylphosphonoamidate intermediate to be then reacted with the alkylated nucleobase 
in the CM reaction. However our synthetic pathway using the one-pot procedure 
reported by Holi (Jansa et al., 2011) proves to be a shorter and efficient approach for 
the synthesis of the allylphosphonoamidate synthon. Moreover the cross metathesis 
conditions appear to be different. Dichloromethane was the solvent of choice in our 
case with branched alkenyl nucleosides whereas for Agrofoglio linear olefin only 
water was effective.  
 
Critical Parameters and Troubleshooting 
The successful preparation of the silylated intermediates 2 and 5 in both Basic 
Protocol 1 and 2 is critical for the outcome of the two synthetic procedures. In 
particular, timing (16 h) is a crucial parameter for this step as in case of too short 
reaction time only partial dealkylation can be observed. The silyl esters 2 and 5 are air 
and moisture sensitive compounds and therefore must be kept at all the time under 
strictly dry atmosphere. 
For Basic Protocol 2, the presence of 2,6-lutidine revealed to be essential for the first 
step as only degradation of the silyl ester intermediate 5 is detected when this acid 
scavenger in not present.  
For the preparation of the aryl phosphonoamidate moiety (ProTide approach) in both 
Basic Protocols 1 and 2, the aryl-alcohol to amino acid ester ratio needs to be 6 to1 in 
favor of the aryloxy reagent to reduce the formation of the bisamidate derivative as 
byproduct. For the cross metathesis reaction, the sequential catalyst loading is a 
crucial parameter to afford the desired transalkylidenation product in good yield.  
The synthetic procedures described in this unit are intended for use only by persons 
with prior training in experimental organic chemistry and thus with knowledge of the 
common chemical laboratory techniques, such as extraction, solvent evaporation, 
column chromatography, TLC and HPLC. Characterization of the products demands 
knowledge of monodimensional (1H, 13C and 31P) and bidimensional (COSY, HSQC, 
HMBC and NOESY) NMR experiments, as well as of mass spectroscopy. Careful 
attention to details of basic organic synthesis methodologies is required. General 
laboratory safety is also of primary concern when hazardous materials are involved. 
Strict adherence to the reported procedures is therefore highly recommended. 
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Understanding Result 
The approaches applied in both Basic protocol 1 and 2 can be applied to prepare 
numerous alkenyl acyclic pyrimidine ProTide derivatives with different aryloxy and 
amino acid ester moieties. Moreover, both the protocols can be adapted to obtain the 
bis-amidate derivatives when in the first step of the two methodologies only the 
amino acid ester is employed. 
The cross metathesis reaction can be significant influenced by the length of the 
acyclic side chain. When the CM procedure reported in Basic Protocol 2 is employed 
for the preparation of aryl vinylphosphonoamidate derivatives, no formation of the 
final product is observed.  
 
Time Considerations 
According to Basic Protocol 1, two weeks are required for the nucleoside preparation 
including purification and characterization of the final ProTide. In case of Basic 
Protocol 2 only one week is needed for the synthesis, characterization of the 
phosphonoamidate prodrug including the preparation of the two olefins and the cross 
metathesis reaction. 
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